Kaposi Sarcoma Associated With Infliximab Treatment

Martínez-Martínez, M.L.; Pérez-García, L.J.; Escario-Travesedo, E.; Ribera-Vaquerizo, P.A.

doi:10.1016/s1578-2190(10)70676-4

Cited by 11 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ours is therefore the second case of KS onset following treatment with adalimumab, and again in the case we have observed, just as in that described by Martinez and Martinez , a close correlation has been highlighted between adalimumab and KS onset and resolution of the lesions on suspension of the drug, despite continuing with corticosteroid therapy. Finally, in consideration of the etiopathogenesis of KS, we believe the matter of whether the onset of angioproliferative disorders may be considered a tumorous or infective side effect may be a topic for further discussion.…”

supporting

confidence: 88%

See 1 more Smart Citation

Kaposi's sarcoma associated with treatment with adalimumab

et al. 2012

View full text Add to dashboard Cite

show abstract

supporting

confidence: 88%

“…and at the same time, cases of adverse infectious or tumorous effects have been described . KS has been reported in three cases: two following treatment with infliximab and one with adalimumab .…”

mentioning

confidence: 94%

Kaposi's sarcoma associated with treatment with adalimumab

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Four patients reported with KS were receiving infliximab therapy, and two patients were using adalimumab treatment. [3][4][5][6][7][8] Similar to our patient, in all of the reported cases, KS developed during the use of the biologic agent. Except for an ulcerative colitis patient with gastrointestinal involvement of KS, 8 the disease was limited to the skin in all of the patients.…”

supporting

confidence: 78%

Aggressive Kaposi’s Sarcoma Associated With Golimumab Therapy

et al. 2018

View full text Add to dashboard Cite

“…To our knowledge, five cases of KS were identified with the use of infliximab, two cases with adalimumab, one with golimumab, and one with certolizumab pegol [7][8][9][10][11][12][13][14][15]. In most of the cases, KS was notably localized to the skin.…”

Section: Discussionmentioning

confidence: 99%

Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy

Mariappan¹,

Desai²,

Locante³

et al. 2021

Cureus

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is a vascular neoplasm caused by human gammaherpesvirus 8 (HHV-8). Four subtypes of KS are described: classic (Mediterranean), epidemic (acquired immunodeficiency syndrome (AIDS)-associated), endemic (sub-Saharan Africa), and iatrogenic. Iatrogenic KS due to tumor necrosis factor-alpha (TNF-α) inhibitor therapy is particularly rare. A 66-year-old female with a history of seropositive rheumatoid arthritis (RA) presented with a skin lesion on her right second toe. Diagnosed with RA four years prior, she failed to respond to methotrexate, hydroxychloroquine, and etanercept. As a result, she was started on adalimumab. Approximately two months into therapy, she presented to the emergency room with a dark brown skin lesion on her right second toe. She underwent excisional biopsy of the mass, which demonstrated a tumor composed of spindle cells forming slit-like spaces with extravasated red blood cells. The tumor was positive for cluster of differentiation 31 (CD31), CD34, and HHV-8 immunostains and negative for smooth muscle antibody (SMA) and desmin immunostains, consistent with Kaposi sarcoma. Human immunodeficiency virus (HIV) serology was negative. The patient was diagnosed with iatrogenic KS. Adalimumab was discontinued. The patient was started on alitretinoin and underwent adjuvant radiation therapy to minimize recurrence. TNF-α is a pro-inflammatory cytokine that has been implicated in many inflammatory diseases and in cell apoptosis. While anti-TNF-α agents have improved outcomes in many immune-mediated diseases, higher rates of infections and malignancy have also been reported. The incidence of KS with anti-TNF-α therapy remains a rare entity. Therefore, it is extremely important for patients receiving biologic agents, including TNF-α inhibitors, to have a close follow-up and receive routine skin evaluation for malignancy. Clinicians should have a high index of suspicion for KS in such non-HIV patients started on immunosuppressive agents.

show abstract

Kaposi Sarcoma Associated With Infliximab Treatment

Cited by 11 publications

References 8 publications

Kaposi's sarcoma associated with treatment with adalimumab

Kaposi's sarcoma associated with treatment with adalimumab

Aggressive Kaposi’s Sarcoma Associated With Golimumab Therapy

Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy

Contact Info

Product

Resources

About